

Audited Financial Statements



Arthritis National Research Foundation

**As of and for the Years Ended
March 31, 2022 and 2021**

*Financial Statements
With Independent Auditors' Report*



Arthritis National Research Foundation

As of and for the Years Ended March 31, 2022 and 2021

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Table of Contents

	<u>Page</u>
Independent Auditors' Report	
Financial Statements	
Statements of Financial Position	3
Statements of Activities and Changes in Net Assets.....	4
Statements of Functional Expenses	6
Statements of Cash Flows	8
Notes to Financial Statements	9

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Arthritis National Research Foundation

Opinion

We have audited the accompanying financial statements of Arthritis National Research Foundation (a not-for-profit organization) (the "Foundation"), which comprise the statement of financial position as of March 31, 2022, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation as of March 31, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report

INDEPENDENT AUDITORS' REPORT (CONTINUED)

Auditors' Responsibilities for the Audit of the Financial Statements (continued)

that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.


In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

March 31, 2021 Financial Statements

The financial statements of Arthritis National Research Foundation as of and for the year ended March 31, 2021, were audited by other auditors, whose report dated January 21, 2022, expressed an unmodified audit opinion on those financial statements.



HASKELL & WHITE LLP

Irvine, California
September 27, 2022

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statements of Financial Position
As of March 31, 2022 and 2021**

	2022	2021
ASSETS		
Assets		
Cash and cash equivalents	\$ 1,455,362	\$ 779,066
Receivables	11,808	42,704
Investments (Note 2)	9,502,164	9,379,638
Other assets	35,506	20,931
Property and equipment, net (Note 3)	36,653	10,849
Total assets	\$ 11,041,493	\$ 10,233,188
LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable and accrued expenses	\$ 60,527	\$ 50,428
Deferred rent	24,421	28,093
Total liabilities	84,948	78,521
Commitments and contingencies (Note 5)		
Net assets		
Without Donor Restrictions		
Undesignated	10,480,441	9,578,563
Board-designated for long term purposes	250,000	250,000
Total without donor restrictions	10,730,441	9,828,563
With Donor Restrictions (Note 4)	226,104	326,104
Total net assets	10,956,545	10,154,667
Total liabilities and net assets	\$ 11,041,493	\$ 10,233,188

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statement of Activities and Changes in Net Assets
For the Year Ended March 31, 2022**

	Without Donor Restrictions	With Donor Restrictions	Total
	<u> </u>	<u> </u>	<u> </u>
Revenues and other support			
Contributions and bequests	\$ 2,969,125	\$ -	\$ 2,969,125
In-kind contributions	135,610	-	135,610
Net realized and unrealized gain on investments	454,966	-	454,966
Interest and dividends, net of investment and advisory fees of \$26,722	114,558	-	114,558
Other income	540	-	540
	<u> </u>	<u> </u>	<u> </u>
Total revenues and other support	3,674,799	-	3,674,799
	<u> </u>	<u> </u>	<u> </u>
Net assets released from restriction	100,000	(100,000)	-
	<u> </u>	<u> </u>	<u> </u>
Total revenues and other support	3,774,799	(100,000)	3,674,799
	<u> </u>	<u> </u>	<u> </u>
Expenses			
Program services			
Research	1,991,402	-	1,991,402
Education	427,351	-	427,351
	<u> </u>	<u> </u>	<u> </u>
Total program services	2,418,753	-	2,418,753
	<u> </u>	<u> </u>	<u> </u>
Supporting activities			
Management and general	201,561	-	201,561
Fundraising	252,607	-	252,607
	<u> </u>	<u> </u>	<u> </u>
Total supporting activities	454,168	-	454,168
	<u> </u>	<u> </u>	<u> </u>
Total expenses	2,872,921	-	2,872,921
	<u> </u>	<u> </u>	<u> </u>
Change in net assets	901,878	(100,000)	801,878
	<u> </u>	<u> </u>	<u> </u>
Net Assets, beginning of year	9,828,563	326,104	10,154,667
	<u> </u>	<u> </u>	<u> </u>
Net Assets, end of year	\$ 10,730,441	\$ 226,104	\$ 10,956,545
	<u> </u>	<u> </u>	<u> </u>

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statement of Activities and Changes in Net Assets
For the Year Ended March 31, 2021**

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Contributions and bequests	\$ 1,268,973	\$ -	\$ 1,268,973
In-kind contributions	134,860	-	134,860
Net realized and unrealized gain on investments	2,924,126	-	2,924,126
Interest and dividends, net of investment and advisory fees of \$23,679	123,323	-	123,323
Other income	42,704	-	42,704
Total revenues and other support	4,493,986	-	4,493,986
Expenses			
Program services			
Research	1,567,125	-	1,567,125
Education	254,691	-	254,691
Total program services	1,821,816	-	1,821,816
Supporting activities			
Management and general	273,643	-	273,643
Fundraising	84,287	-	84,287
Total supporting activities	357,930	-	357,930
Total expenses	2,179,746	-	2,179,746
Change in net assets	2,314,240	-	2,314,240
Net Assets , beginning of year, as Previously Reported	7,504,037	336,390	7,840,427
Prior Period Adjustment (Note 1)	10,286	(10,286)	-
Net Assets , beginning of year, as Restated	7,514,323	326,104	7,840,427
Net Assets , end of year	\$ 9,828,563	\$ 326,104	\$ 10,154,667

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statement of Functional Expenses
For the Year Ended March 31, 2022**

	Program Services			Supporting Activities			Total Expenses
	Research	Education	Total	Management and General	Fundraising	Total	
Research grants, net of \$1,932 of grant funds returned	\$ 1,598,068	\$ -	\$ 1,598,068	\$ -	\$ -	\$ -	\$ 1,598,068
Salaries and wages	146,428	170,451	316,879	85,781	159,387	245,168	562,047
Communication and outreach	71,322	78,400	149,722	22,081	28,308	50,389	200,111
Professional services	51,675	58,801	110,476	24,664	13,919	38,583	149,059
Meetings, retreats and travel	33,093	25,553	58,646	14,392	4,520	18,912	77,558
Office rent	25,806	26,106	51,912	2,779	6,451	9,230	61,142
Payroll taxes	12,212	10,464	22,676	7,604	14,638	22,242	44,918
Office expenses	11,533	10,741	22,274	13,069	6,661	19,730	42,004
Health insurance	16,937	17,217	34,154	781	4,401	5,182	39,336
State registrations and licenses	4,892	8,532	13,424	2,170	3,437	5,607	19,031
Printing	2,048	4,269	6,317	5,597	2,323	7,920	14,237
Postage	4,778	2,947	7,725	4,813	95	4,908	12,633
Bank and credit card fees	2,635	2,790	5,425	5,031	2,015	7,046	12,471
Insurance	4,105	4,210	8,315	1,409	1,172	2,581	10,896
Research communication and support	2,791	3,391	6,182	367	367	734	6,916
Telephone and internet	1,122	1,122	2,244	2,934	1,262	4,196	6,440
401(k) plan	1,652	1,602	3,254	750	1,667	2,417	5,671
Payroll processing fees	225	225	450	3,365	56	3,421	3,871
Miscellaneous	80	530	610	983	1,928	2,911	3,521
Depreciation and amortization	-	-	-	2,991	-	2,991	2,991
Total expenses	\$ 1,991,402	\$ 427,351	\$ 2,418,753	\$ 201,561	\$ 252,607	\$ 454,168	\$ 2,872,921

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statement of Functional Expenses
For the Year Ended March 31, 2021**

	Program Services			Supporting Activities			Total Expenses
	Research	Education	Total	Management and General	Fundraising	Total	
Research grants, net of \$36,530 of grant funds returned	\$ 1,363,470	\$ -	\$ 1,363,470	\$ -	\$ -	\$ -	\$ 1,363,470
Salaries and wages	27,118	103,222	130,340	27,751	44,851	72,602	202,942
Communication and outreach	96,346	77,355	173,701	5,461	3,382	8,843	182,544
Professional services	7,186	7,186	14,372	115,514	1,788	117,302	131,674
Meetings, retreats and travel	56	285	341	14	14	28	369
Office rent	20,426	18,908	39,334	14,460	5,675	20,135	59,469
Payroll taxes	3,833	3,743	7,576	1,926	5,161	7,087	14,663
Office expenses	8,854	7,328	16,182	6,617	5,480	12,097	28,279
Health insurance	5,429	6,118	11,547	3,323	1,110	4,433	15,980
Printing	2,133	6,104	8,237	5,385	591	5,976	14,213
Postage	5,221	80	5,301	440	318	758	6,059
Bank and credit card fees	312	979	1,291	1,354	5,169	6,523	7,814
Insurance	1,765	2,063	3,828	586	726	1,312	5,140
Research communication and support	21,321	13,960	35,281	384	4,359	4,743	40,024
Telephone and internet	994	1,261	2,255	1,162	253	1,415	3,670
Payroll processingn fees	-	123	123	2,562	898	3,460	3,583
Miscellaneous	2,661	5,976	8,637	1,129	4,512	5,641	14,278
Depreciation and amorization	-	-	-	950	-	950	950
Write-off of note receivable	-	-	-	84,625	-	84,625	84,625
 Total expenses	\$ 1,567,125	\$ 254,691	\$ 1,821,816	\$ 273,643	\$ 84,287	\$ 357,930	\$ 2,179,746

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**Statements of Cash Flows
For the Years Ended March 31, 2022 and 2021**

	2022	2021
Cash flows from operating activities		
Change in net assets	\$ 801,878	\$ 2,314,240
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Net realized and unrealized gain on investments	(454,966)	(2,924,126)
Write-off of note receivable	-	84,625
Depreciation and amortization	2,991	950
Deferred rent	(3,672)	8,278
Changes in operating assets and liabilities		
Receivables	30,896	(42,704)
Other assets	(14,575)	(4,937)
Accounts payable and accrued expenses	10,099	37,413
Net cash provided by (used in) operating activities	372,651	(526,261)
Cash flows from investing activities		
Proceeds from sales of investments	3,263,072	2,339,497
Purchases of investments	(2,930,632)	(1,839,191)
Purchases of property and equipment	(28,795)	(5,602)
Net cash provided by investing activities	303,645	494,704
Net Change in Cash and Cash Equivalents	676,296	(31,557)
Cash and cash equivalents, beginning of year	779,066	810,623
Cash and cash equivalents, end of year	\$ 1,455,362	\$ 779,066

See accompanying notes to the financial statements and independent auditors' report.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies

Purpose and Organization

Arthritis National Research Foundation (the “Foundation”) was incorporated on May 2, 1952, as a California nonprofit corporation. The Foundation provides arthritis and autoimmune research grants to scientists at major universities and research institutes across America. One- and two-year arthritis research grants allow these early career scientists to develop their important research to a stage where it can be continued and further supported by other national agencies.

Since 1970, the Arthritis National Research Foundation has funded arthritis research to understand the causes, prevention and development of new treatments for osteoarthritis, rheumatoid arthritis, psoriatic arthritis, lupus, juvenile arthritis and other autoimmune diseases. Since then, the Foundation has funded over 250 scientists, and our research projects have led to new information and treatments.

The Foundation’s mission statement is as follows:

“The mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases.”

Basis of Accounting

The Foundation prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

March 31, 2021 - Prior Period Adjustment

The March 31, 2021 prior period adjustment reflects an amount that was improperly included in beginning net assets with donor restrictions. The adjustment reflects the reclassification from net assets with donor restrictions to net assets without donor restrictions.

Reclassification

Certain amounts in the statement of functional expenses for the year ended March 31, 2021, have been reclassified to conform to the 2022 statement of functional expenses presentation.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies (continued)

Classification of Net Assets

U. S. GAAP requires that the Foundation report information regarding its financial position and activities according to two classes of net assets: without donor restriction and with donor restrictions. Accordingly, the net assets of the Foundation are classified and reported as described below:

Without Donor Restrictions - Those net assets and activities which represent the portion of expendable funds that are available to support the Foundation's operations. A portion of these net assets may be designated by the Board of Directors for specific purposes, and as of March 31, 2022 and 2021, the Foundation's Board of Directors has designated \$250,000 for long-term purposes.

With Donor Restrictions - Donor-restricted net assets represent those net assets which are donor-restricted for (a) support of specific operating activities; (b) investment for a specified term; (c) use in a specified future period; (d) acquisition of long-lived assets; (e) assets donated with stipulations by the donor that they be used for a specified purpose, be preserved, not be sold; or (f) be invested to provide a permanent source of income. Donor-restricted net assets are described in Note 4.

Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying amounts of cash and cash equivalents, receivables and accounts payable approximate fair value because of the short maturity of these instruments. The fair value of the Foundation's investments are described in Note 2.

Investments

Investments in equity and debt securities are carried at fair value based on quoted market prices. Investments in bonds are carried at fair value based upon observable inputs. Unrealized gains and losses are included in the statements of activities and changes in net assets.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies (continued)

Property and Equipment

The Foundation capitalizes acquisitions of property and equipment with a cost or value in excess of \$1,000 and with an estimated useful life beyond one year. Purchased assets are recorded at cost. Depreciation and amortization are calculated using the straight-line method based upon estimated useful lives, which ranges from three to seven years. Leasehold improvements are amortized over the shorter of the asset's useful life or the lease term. Maintenance and repairs are charged to expense as incurred; major renewals and betterments are capitalized. The cost and accumulated depreciation and amortization of assets sold or retired are removed from the respective accounts and any gain or loss is reflected in the statements of activities and changes in net assets.

Deferred Rent

The Foundation leases office space under a lease agreement that is subject to scheduled rent increases. Rent expense is recognized on the straight-line basis over the term of the lease and the difference between the average rental amount charged and amount payable under the lease is included in deferred rent in the accompanying statements of financial position. As of March 31, 2022 and 2021, deferred rent was \$24,421 and \$28,093, respectively.

Revenue Recognition

Contributions and Bequests

The Foundation recognizes all unconditional contributions when they are received or unconditionally promised. Unconditional contributions are recognized based on the existence or absence of donor-imposed restrictions. Unconditional contributions with donor-imposed restrictions may be expendable or are required to be held in perpetuity. Conditional contributions are recognized when related conditions are substantially met.

The satisfaction of donor-imposed restrictions on a contribution is recognized when the corresponding expenditures are incurred or when the time restriction expires. This occurs by increasing one class of net assets and decreasing another in the statement of activities and changes in net assets. Such transactions are recorded as net assets released from restrictions and are reported separately from other transactions. Contributions with donor-imposed restrictions that are received and whose restrictions are satisfied in the same year as related funds are expended are reported as contributions without donor-imposed restrictions in the accompanying financial statements.

Bequests are not recognized as support until the amount of the bequest is known; the Foundation is certain that based on the estate's net assets, the amount bequeathed is realizable; and the probate court has declared the will valid.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies (continued)

Contributed Goods and Services

Donated material and equipment are recorded as contributions at their fair value on the date of receipt. Such donations are reported as without donor-restricted support unless the donor has restricted the donated asset to a specific purpose. Assets donated with explicit restrictions regarding their use are reported as with donor-restricted support. Absent donor stipulations regarding how long those donated assets must be maintained, the Foundation reports expirations of donor restrictions when the donated or acquired assets are placed in service as instructed by the donor. The Foundation reclassifies net assets with restrictions to net assets without restrictions at that time.

The Foundation records contribution revenue for certain services received at the fair value of those services, if the services (a) create or enhance non-financial assets, or (b) require specialized skills, are provided by individuals possessing those skills, and would be purchased if not donated.

For the years ended March 31, 2022 and 2021, contributed advertising services totaled \$135,610 and \$134,860, respectively.

Investment Income

Dividends are recorded on the ex-dividend date. Interest income is recognized on the accrual basis. Investment transactions are accounted for on a trade-date basis. Realized and unrealized investment gains (losses) and investment income (losses) are recognized in the year earned.

Grant Awards

Grants are characterized as either conditional or unconditional. Conditional grants are those that depend upon the occurrence of a specified future and uncertain event to bind the Foundation. These grants are not reflected in the financial statements until the period in which the conditions upon which they depend are substantially met, that is, when they become unconditional.

Advertising

The costs of advertising are charged to expense as incurred. Advertising expense was \$140,213 and \$137,115 for the years ended March 31, 2022 and 2021, respectively, and are included in communication and outreach on the statements of functional expenses.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies (continued)

Income Taxes

The Foundation is a qualified organization exempt from federal income and state franchise taxes under §501(c)(3) of the Internal Revenue Code (“IRC”) and §23701d of the California Revenue and Taxation Code, respectively. Accordingly, the Foundation is exempt from federal and California income taxes and is not liable for federal unemployment taxes.

U.S. GAAP requires management to evaluate the tax positions taken and recognize a tax liability (or asset) if the Foundation has taken an uncertain position that more-likely-than-not would not be sustained upon examination by taxing authorities. Management evaluated the Foundation’s tax positions and concluded that it maintained its tax-exempt status and had taken no uncertain tax positions that would require adjustment to the financial statements. Therefore, no provision or liability for unknown income taxes has been included in the financial statements. The Foundation’s tax returns are subject to examination by federal and state taxing authorities. However, there are no examinations in progress nor are there any pending.

Concentrations of Risk

Financial Instruments

Financial instruments which potentially subject the Foundation to concentrations of credit risk consist principally of cash and investments.

Cash and Cash Equivalents

The Foundation considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Foundation maintains its cash and cash equivalents in various bank accounts which, at times, may exceed federally insured limits. The Foundation has not experienced any losses in such accounts. The Foundation is exposed to credit risk in the event of default by its primary banking institution to the extent amounts exceed FDIC insured amounts.

Investments

The Foundation invests in various investments that are not covered by federal insurance. These investments are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the Foundation’s balances and the amounts reported in the statement of financial position. The Foundation’s management attempts to minimize its exposure to these risks by closely monitoring all investments in accordance with the Foundation’s policies.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

1. Organization and Summary of Significant Accounting Policies (continued)

Contributions and Bequests

For the year ended March 31, 2022, 13% of contributions and bequests were received from one donor. For the year ended March 31, 2021, 20% of contributions and bequests were received from one donor.

Functional Expense Allocations

The costs of providing program services and other supporting activities have been summarized on a functional basis in the statements of activities and changes in net assets and functional expenses. Expenses have been allocated between program, management and general, and fundraising based on direct identification when possible, and allocation if a natural class of expense benefits more than one program or function. Salaries and related expenses are allocated based on the estimated time and efforts of involvement in different activities. Other expenses that require allocation are based on estimates of the benefits received.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). ASU 2016-02 will require lessees to recognize for all leases (with terms of more than 12 months) at the commencement date the following: a) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and b) a right of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. This ASU’s effective date had two one-year delays and is now effective for fiscal years beginning after December 15, 2021. Management is evaluating the impact of this guidance.

In June 2016, FASB issues ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The standard is effective for fiscal years beginning after December 31, 2022; and early adoption is permitted. Management is evaluating the impact of this guidance.

In September 2020, the FASB issued ASU 2020-07, Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets. ASU 2020-07 requires a not-for-profit entity to present contributed nonfinancial assets in the statement of activities and changes in net assets as a line item that is separate from contributions of cash or other financial assets. ASU 2020-07 also requires additional qualitative and quantitative disclosures about contributed nonfinancial assets received, disaggregated by category. The guidance should be applied on a retrospective basis, and is applicable for annual reporting periods beginning after June 15, 2021. Management is evaluating the impact of this guidance.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

2. Fair Value Measurements

The Foundation's financial assets and liabilities that are carried at fair value have been classified, for disclosure purposes, based on a hierarchy that gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset or a liability's classification is based on the lowest level input that is significant to its measurement.

Level 1 Inputs are unadjusted quoted prices for identical assets or liabilities in active markets accessible at the measurement date.

Level 2 Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities from those willing to trade in markets that are not active, or inputs that are derived principally from or corroborated by observable market data by correlation or other means for the term of the instrument.

Level 3 Certain inputs are unobservable (supported by little or no market activity) and significant to the fair value measurement. Unobservable inputs reflect the Foundation's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date.

Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a description of the valuation methodologies used for assets measured at fair value. There were no changes to the valuation methodologies during the years ended March 31, 2022 and 2021.

Mutual Funds

The fair value of mutual funds are based on the daily closing prices as reported by the fund. Mutual funds held by the Foundation are open-end mutual funds that are registered with the United States Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Foundation are deemed to be actively traded.

Domestic Stocks

The fair value of domestic stocks are based on the closing price reported on the active market on which the individual securities are traded.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

2. Fair Value Measurements (continued)

Exchange Traded Funds (“ETFs”)

The Foundation’s ETFs hold assets such as stocks, commodities, or bonds. Investments in ETFs are included in Level 1 of the fair value hierarchy and their fair value is based on the closing price reported on the active market on which the respective securities are traded.

Corporate and Government Bonds

The fair value of corporate and government bonds is based on pricing models maximizing the use of observable inputs for similar securities.

In accordance with the fair value hierarchy, investments measured at fair value at March 31, 2022 and 2021 are as follows:

	Investments at Fair Value as of March 31, 2022			
	Level 1	Level 2	Level 3	Total
Mutual funds	\$ 3,949,017	\$ -	\$ -	\$ 3,949,017
Domestic stocks	4,667,632	-	-	4,667,632
Corporate bonds	-	480,215	-	480,215
Government bonds	-	405,300	-	405,300
Total investments at fair value	\$ 8,616,649	\$ 885,515	\$ -	\$ 9,502,164
	Investments at Fair Value as of March 31, 2021			
	Level 1	Level 2	Level 3	Total
Mutual funds	\$ 4,520,070	\$ -	\$ -	\$ 4,520,070
Domestic stocks	3,937,414	-	-	3,937,414
Exchange traded funds	120,771	-	-	120,771
Government bonds	-	488,395	-	488,395
Corporate bonds	-	312,988	-	312,988
Total investments at fair value	\$ 8,578,255	\$ 801,383	\$ -	\$ 9,379,638

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

2. Fair Value Measurements (continued)

Investment income is as follows for the years ended March 31, 2022 and 2021:

	2022	2021
Dividends and interest income	\$ 141,280	\$ 147,002
Realized gain on sale of investments	683,630	875,067
Unrealized (loss) gain on investments	(228,664)	2,049,059
	<u>596,246</u>	<u>3,071,128</u>
Less: investment fees	(26,722)	(23,679)
	<u>\$ 569,524</u>	<u>\$ 3,047,449</u>

3. Property and Equipment

Property and equipment at March 31, 2022 and 2021, consist of the following:

	2022	2021
Furniture and equipment	\$ 7,943	\$ 6,324
Leasehold improvements	5,601	5,601
Computer hardware and software	27,176	-
	<u>40,720</u>	<u>11,925</u>
Less: accumulated depreciation and amortization	(4,067)	(1,076)
	<u>\$ 36,653</u>	<u>\$ 10,849</u>

Depreciation and amortization expense for the years ended March 31, 2022 and 2021, were \$2,991 and \$950, respectively.

4. Net Assets with Donor Restrictions

The assets with donor restrictions consist of the following at March 31, 2022 and 2021:

	2022	2021
Subject to expenditure for specified purpose:		
Ankylosing Spondylitis research	<u>\$ 226,104</u>	<u>\$ 326,104</u>

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

5. Commitments and Contingencies

Lease Contract

The Foundation has an operating lease agreement related to its office space, which expires in May 2025. The schedule of noncancellable minimum lease commitments are as follows:

For the Years Ending March 31,	
2023	\$ 65,011
2024	66,961
2025	68,969
2026	11,722
	<u>212,663</u>
	<u>\$ 212,663</u>

For the years ended March 31, 2022 and 2021, rent expense was \$61,142 and \$59,469, respectively.

Retirement Plan

The Foundation implemented a 401(k) Retirement Plan (the “Plan”) during January 2022. The Plan covers all eligible employees with over three months of service. The Foundation’s mandatory contribution to the Plan for the year ended March 31, 2022 was \$5,671.

Contingencies

From time to time, the Foundation may be involved in legal and administrative proceedings and claims of various types. The Foundation records a liability in its financial statements for these matters when a loss is known and is considered probable and the amount can be reasonably estimated. Management reviews these estimates in each reporting period as additional information becomes known and adjusts the loss estimate when appropriate. If a loss is probable but the amount of loss cannot be reasonably estimated, the Foundation discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). Gain contingencies are not recognized until they are realized. Legal costs incurred in connection with loss contingencies are expensed as incurred.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

5. Commitments and Contingencies (continued)

COVID-19

The global economy has been impacted by a pandemic outbreak of the COVID-19 virus, and related variants, including the United States of America beginning March 2020. This has resulted in many businesses temporarily closing or working in remote environments. The Foundation has been able to continue most of its operations in a remote environment. The Foundation does not yet know the full extent of the potential impact, if any, this may have on its business operations, and no specific material adverse matters have been identified or estimable. The Foundation continues to monitor the COVID-19 situation closely and revise its estimates in future periods, as necessary.

6. Related Party Transactions

Two members of the Board of Directors are vice president and managing partner, respectively, of financial institutions that manage the Foundation's investments. During the years ended March 31, 2022 and 2021, \$26,722 and \$23,679 was paid to these financial institutions for investment and advisory fees.

7. Liquidity and Availability of Resources

The Foundation regularly monitors liquidity to meet its annual operating needs and other contractual commitments, while also striving to preserve the principal and return on investment of its funds. The Foundation's financial assets available within one year of the statement of financial position date for general expenditures are as follows:

Cash and cash equivalents	\$ 1,455,362
Receivables	11,808
Investments	<u>9,502,164</u>
Total financial assets	10,969,334
Less: Donor-restricted funds	(226,104)
Less: Board-designated funds	<u>(250,000)</u>
Total financial assets available to meet general expenditures within one-year	<u><u>\$ 10,493,230</u></u>

ARTHRITIS NATIONAL RESEARCH FOUNDATION

Notes to Financial Statements (continued) For the Years Ended March 31, 2022 and 2021

7. Liquidity and Availability of Resources (continued)

Management is focused on sustaining the financial liquidity of the Foundation throughout the year. This is done through monitoring and reviewing the Foundation's cash flow needs on a weekly basis. As part of its liquidity plan, the Foundation maintains enough cash to cover estimated annual grants and operating costs. The investments in the table above are available to meet cash flow needs because they can be liquidated at any time.

8. Subsequent Events

The Foundation has evaluated all subsequent events through September 27, 2022, the date the financial statements were available to be issued. There are no events identified requiring recognition or disclosure in the financial statements.